Disc Medicine, Inc. (NASDAQ:IRON - Free Report) - Equities researchers at Wedbush dropped their Q4 2024 earnings estimates for shares of Disc Medicine in a note issued to investors on Tuesday, November 12th. Wedbush analyst D. Nierengarten now expects that the company will post earnings per share of ($0.94) for the quarter, down from their previous forecast of ($0.89). Wedbush has a "Outperform" rating and a $83.00 price target on the stock. The consensus estimate for Disc Medicine's current full-year earnings is ($4.15) per share. Wedbush also issued estimates for Disc Medicine's Q1 2025 earnings at ($0.98) EPS, Q2 2025 earnings at ($1.01) EPS, Q3 2025 earnings at ($1.04) EPS, Q4 2025 earnings at ($1.08) EPS, FY2025 earnings at ($4.10) EPS, FY2026 earnings at ($4.19) EPS and FY2027 earnings at $2.20 EPS.
Several other research firms have also recently weighed in on IRON. Wells Fargo & Company began coverage on Disc Medicine in a report on Thursday, August 22nd. They set an "overweight" rating and a $75.00 price objective on the stock. Jefferies Financial Group assumed coverage on shares of Disc Medicine in a research note on Wednesday, October 23rd. They issued a "buy" rating and a $89.00 price target on the stock. Raymond James raised shares of Disc Medicine from an "outperform" rating to a "strong-buy" rating and increased their price objective for the stock from $66.00 to $110.00 in a research report on Monday, November 4th. Cantor Fitzgerald restated an "overweight" rating and set a $85.00 price objective on shares of Disc Medicine in a report on Tuesday, October 15th. Finally, HC Wainwright upped their target price on shares of Disc Medicine from $70.00 to $118.00 and gave the stock a "buy" rating in a research note on Wednesday. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Disc Medicine has an average rating of "Buy" and a consensus price target of $85.80.
View Our Latest Research Report on Disc Medicine
IRON stock opened at $60.67 on Friday. Disc Medicine has a 1-year low of $25.60 and a 1-year high of $77.60. The business's 50-day moving average price is $51.02 and its two-hundred day moving average price is $44.75.
Disc Medicine (NASDAQ:IRON - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.89) earnings per share for the quarter, topping analysts' consensus estimates of ($1.04) by $0.15.
In other Disc Medicine news, Director William Richard White sold 7,136 shares of the firm's stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $58.61, for a total value of $418,240.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 7,538 shares of company stock valued at $437,875 in the last three months. 4.24% of the stock is currently owned by corporate insiders.
Several large investors have recently made changes to their positions in IRON. Amalgamated Bank grew its holdings in Disc Medicine by 76.9% during the second quarter. Amalgamated Bank now owns 568 shares of the company's stock worth $26,000 after purchasing an additional 247 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Disc Medicine by 45.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company's stock valued at $54,000 after buying an additional 337 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Disc Medicine during the 2nd quarter worth approximately $129,000. Quest Partners LLC acquired a new position in shares of Disc Medicine during the 3rd quarter worth approximately $131,000. Finally, Quantbot Technologies LP bought a new stake in Disc Medicine in the 3rd quarter valued at $146,000. Institutional investors and hedge funds own 83.70% of the company's stock.
Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Disc Medicine, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Disc Medicine wasn't on the list.
While Disc Medicine currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.